Skip to main content
. Author manuscript; available in PMC: 2022 Oct 13.
Published in final edited form as: Sci Transl Med. 2021 Sep 8;13(610):eabf0376. doi: 10.1126/scitranslmed.abf0376

Fig. 7. Long-term treatment with anti-LTBP4 antibody dosing reduced muscle fibrosis in dystrophic mice.

Fig. 7.

(A) Fibrosis as shown by Masson’s trichrome (blue) or collagen content as seen by Sirius Red (red) after mouse anti-LTBP4 (SBI-3m) or human anti-LTBP4 (SBI-3h) antibody treatment compared to PBS control or human IgG controls in mdx/hLTBP4 diaphragm muscle. Normal wild-type diaphragm staining is included for comparison. Scale bars, 100 μm. (B) Hydroxyproline (HOP) concentration after mouse anti-LTBP4 (SBI-3m) or human anti-LTBP4 (SBI-3h) antibody treatment compared to PBS and IgG human controls. Hydroxyproline concentration after SBI-3h antibody treatment was reduced so that it was not statistically different from wild type. (C) Whole-body plethysmography measures respiratory muscle function. Enhanced pause (Penh)/body mass was reduced (improved) with SBI-3m and SBI-3h treatment compared to controls. *P < 0.05 by one-way ANOVA. n ≥ 9 mice per group, except n = 4 WT controls.